SCHEMBL2960119

SCHEMBL2960119

Cc1cccc(C(=O)O)c1S

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.61
KDM4E B2RXH2 4/20 0.61
HPGD P15428 3/20 0.61
HSD17B10 Q99714 2/20 0.61
MYC P01106 1/20 0.55
CYP3A4 P08684 2/20 0.52
CYP2C9 P11712 2/20 0.52
KMT2A Q03164 2/20 0.52
POLB P06746 2/20 0.50
MAPT P10636 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
NAPRT Q6XQN6 2/20 0.49
MEN1 O00255 1/20 0.49
AKR1B10 O60218 1/20 0.49
TRPA1 O75762 1/20 0.49
ABCB11 O95342 1/20 0.49
DHFR P00374 1/20 0.49
LMNA P02545 1/20 0.49
MPO P05164 1/20 0.49
CYP1A2 P05177 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2162181 0.84 MAPT (0.61) ALDH1A1KDM4EHPGDHSD17B10MYC
SCHEMBL7908528 0.83 PARP1 (0.46) ALDH1A1KDM4EHPGDHSD17B10MYC
SCHEMBL30786246 0.83 PARP1 (0.46) ALDH1A1KDM4EHPGDHSD17B10MYC
SCHEMBL1545846 0.83 BRPF1 (0.46) ALDH1A1KDM4EHPGDHSD17B10MYC
SCHEMBL28110045 0.80 AKR1C3 (0.52) ALDH1A1KDM4EHPGDHSD17B10MYC
SCHEMBL3073816 0.80 CYP1A2 (0.44) ALDH1A1KDM4EHPGDHSD17B10MYC
SCHEMBL8962212 0.80 HSD17B10 (0.63) ALDH1A1KDM4EHPGDHSD17B10MYC
Toluic Acid SCHEMBL9329186 0.79 ALDH1A1 (0.62) ALDH1A1KDM4EHPGDHSD17B10MYC
SCHEMBL28557547 0.78 ALDH1A1 (0.41) ALDH1A1KDM4EHPGDHSD17B10MYC
SCHEMBL13159071 0.78 TSHR (0.50) ALDH1A1KDM4EHPGDHSD17B10MYC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3859804-B1 SEMICONDUCTOR DEVICE HAVING QUANTUM DOTS CANON KK (JP) 2024-08-07 EP claimed
CN-108704664-A A kind of production method of furandicarboxylic acid heptyl ester catalyst 张玲 2018-10-26 CN claimed
US-12245446-B2 Semiconductor device having quantum dots, display device, imaging system, and moving body CANON KABUSHIKI KAISHA (JP) 2025-03-04 US disclosed
EP-3859804-B1 SEMICONDUCTOR DEVICE HAVING QUANTUM DOTS CANON KK (JP) 2024-08-07 EP disclosed
US-20240162643-A1 ELECTRICAL CONNECTION MEMBER MATERIAL AND ELECTRICAL CONNECTION MEMBER SUMITOMO ELECTRIC INDUSTRIES, LTD. (JP) 2024-05-16 US disclosed
CN-116283785-A Sulfhydryl compound and preparation method thereof 华能武汉发电有限责任公司 2023-06-23 CN disclosed
CN-109311839-B Methylamine derivatives as lysyl oxidase inhibitors for the treatment of cancer 癌症研究协会皇家癌症医院 2021-11-02 CN disclosed
CN-113285024-A Semiconductor device having quantum dots, display device, imaging system, and moving object 佳能株式会社 2021-08-20 CN disclosed
US-20210242416-A1 SEMICONDUCTOR DEVICE HAVING QUANTUM DOTS, DISPLAY DEVICE, IMAGING SYSTEM, AND MOVING BODY CANON KABUSHIKI KAISHA (JP) 2021-08-05 US disclosed
EP-3859804-A2 SEMICONDUCTOR DEVICE HAVING QUANTUM DOTS CANON KABUSHIKI KAISHA (JP) 2021-08-04 EP disclosed
WO-2021131845-A1 RADIATION-SENSITIVE RESIN COMPOSITION AND METHOD FOR FORMING PATTERN JSR株式会社 2021-07-01 WO disclosed
US-20090082343-A1 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-03-26 US disclosed
US-7399759-B2 1, 3-benzothiazinone derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-15 US disclosed
CN-1691944-A Oxadiazoles as modulators of metabotropic glutamate receptor-5 ASTRAZENECA AB (SE) 2005-11-02 CN disclosed
US-20050032786-A1 1, 3-benzothiazinone derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-02-10 US disclosed
EP-1424336-A1 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2004-06-02 EP disclosed
CN-1441637-A Compositions for repelling crawling insects BAYER AG (DE) 2003-09-10 CN disclosed
WO-1998055475-A1 GUANIDINE DERIVIATIVES AS INHIBITORS OF NA+/H+ EXCHANGE IN CELLS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-12-10 WO disclosed
US-4440941-A Aroyl-aminoacids, amides and esters thereof USV PHARMACEUTICAL CORPORATION (US) 1984-04-03 US disclosed
EP-0054936-A1 Aroyl amino acids USV PHARMACEUTICAL CORPORATION (US) 1982-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082343-A1 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF MIF, MORF4L1, FOXM1 ALDH1A1 273/4885KDM4E 3627/4885HPGD 1550/4885
US-20050032786-A1 1, 3-benzothiazinone derivatives and use thereof MIF, MORF4L1, FOXM1 ALDH1A1 273/4885KDM4E 3627/4885HPGD 1550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.